Serum melatonin as a potential biomarker for COVID-19 severity.

ABSTRACT: With the ongoing global burden of COVID-19, identifying reliable biomarkers to predict disease severity remains a clinical priority. Melatonin, a hormone with immunomodulatory and antioxidant properties, has garnered attention for its potential role in regulating inflammation during viral infections. However, the relationship between serum melatonin levels and COVID-19 severity remains poorly understood. This study aimed to evaluate the correlation between serum melatonin concentration and COVID-19 severity to identify potential prognostic biomarkers. A cohort study was conducted, including patients diagnosed with COVID-19 between June 2020 and July 2022. Serum melatonin levels in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) were measured and analyzed

SUBMITTER: Tamanna S 

PROVIDER: S-EPMC12267769 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature